Loading…

Loading grant details…

Active HORIZON European Commission

EARLY COLORECTAL CANCER: PATIENT-TARGETED AND ORGAN PRESERVING TREATMENT ECOPOP


Funder European Commission
Recipient Organization Universitetet I Oslo
Country Norway
Start Date Jan 01, 2025
End Date Dec 31, 2029
Duration 1,825 days
Number of Grantees 18
Roles Participant; Associated Partner; Coordinator; Third Party
Data Source European Commission
Grant ID 101156165
Grant Description

Incidence and mortality of colorectal cancer (CRC) is the second leading cause of cancer death in Europe.

With current screening programs in most European countries, many CRCs are detected in an early and curable stage with excellent prognosis. The current standard treatment for early CRC is surgical tumour removal. This is considered as overly invasive especially for the growing number of elderly and frail patients.

Expanding technical possibilities of local tumour removal by flexible endoscopy along with initial data supporting its oncological safety open the way to organ preserving therapy. This may result in avoiding surgery and improved patients´ quality of life (QoL).

However, high-quality, long-term oncological outcome data of endoscopic removal as compared to surgery are lacking, and precise oncological risk criteria prior to the start of the therapy are urgently needed.

The current project has two major aims: a) to assess oncological efficacy, safety, and patient QoL of local endoscopic removal of early CRC as compared to surgery in 3 randomized trials, and b) to develop and test criteria in this patient population to primarily identify high-risk lesions based on novel biomarkers, endoscopic imaging, and other clinical criteria, also within an artificial intelligence-guided treatment algorithm.

We propose to provide state-of-the-art assessment of new, sustainable, less invasive treatment modalities for early-stage CRC and determine patient preferences around these therapies. We will perform large, international head-to-head randomized clinical trials.

These trials will allow carbon cost effectiveness analyses, biomarker research and development of clinical practice guidelines to carve out the next-generation best clinical practice for patients with early-stage CRC.

Our proposal aims at less invasive, sustainable organ-preserving therapies maintaining high oncological efficacy and helping physicians and patients to perform individual shared decision-making.

All Grantees

Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie -Panstwowy Instytut Badawczy; Centre Hospitalier Universitaire de Limoges; Sodersjukhuset Ab; Universiteit Gent; Universitat Basel; Digestive Cancers Europe Dice; Oslo Universitetssykehus Hf; Gdanski Uniwersytet Medyczny; Azienda Sanitaria Locale Roma 6; Veterans Education and Research Association of Northern New England, Inc.; Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer; Humanitas Mirasole Spa; Universitaetsklinikum Hamburg-Eppendorf; Universitetet I Oslo; Karolinska Institutet; Hospital Clinic de Barcelona; Stiftelsen Magic Evidence Ecosystem; Katholieke Universiteit Leuven

Advertisement
Apply for grants with GrantFunds
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant